Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 4/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27757307 | 1.00 | NPC1 (0.52) | NPC1EPHX2CCR3THRBHPGD | |
| SCHEMBL14368694 | 0.87 | MCHR1 (0.52) | CCR3HPGDSIGMAR1 | |
| SCHEMBL28783269 | 0.87 | MCHR1 (0.52) | CCR3HPGDSIGMAR1 | |
| SCHEMBL28779126 | 0.85 | CCR3 (0.56) | CCR3SIGMAR1ALDH1A1ACKR3 | |
| SCHEMBL14368761 | 0.82 | C3AR1 (0.50) | SIGMAR1ALDH1A1 | |
| SCHEMBL27757311 | 0.82 | C3AR1 (0.50) | SIGMAR1ALDH1A1 | |
| SCHEMBL14368748 | 0.81 | TP53 (0.48) | NPC1HPGDSIGMAR1ALDH1A1RAB9A | |
| SCHEMBL27778439 | 0.81 | TP53 (0.48) | NPC1HPGDSIGMAR1ALDH1A1RAB9A | |
| SCHEMBL14368730 | 0.79 | POLB (0.58) | CCR3HPGDSIGMAR1ALDH1A1ACKR3 | |
| SCHEMBL28783273 | 0.79 | POLB (0.58) | CCR3HPGDSIGMAR1ALDH1A1ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007126362-A1 | COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN TREATING PAIN, ALZHEIMER'S DISEASE AND/OR SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | WO | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | OPRL1, OPRM1, SIGMAR1 | NPC1 1012/4885EPHX2 2383/4885CCR3 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.